According to the U.S. CDC in 2015 there were 18.4 million people over the age of 18 suffering from asthma, and another 6.2 million children < age 18, translating to a total of 16% of the U.S. population. 185 children and 3,262 adults died from asthma in 2007 for a total of 9 people dying each day that year. Loss of life and QUALITY of life aren’t the only associated costs of this diseases. Our country spent $56 billion (2007) in medical fees, forgone school and work days, and early deaths.
To date, the recommended guidelines for treating asthma neglect the body of research linking asthma to infection. Rescue inhalers are prescribed for mild or intermittent asthma. Inhaled corticosteroids (ICS) are the next step for poorly controlled, more frequent symptoms. Patients who do not respond adequately to to ICS then typically receive an added inhaled long-acting bronchodilator (LABA), and or a variety of other medications (oral and/or injectable biologic therapy). In spite of these interventions many patients remain poorly controlled, severely impacting quality of life.
Regardless of peer-reviewed, published research and articles on the role that infection plays in asthma, the medical community at large has yet to integrate this knowledge into clinical practice. Antimicrobials have been found to be effective for a statistically significant number of patients suffering with asthma. There is an urgent need for larger studies to determine the ideal antimicrobial regimen (single versus combination therapy) and duration of treatment. Since the implicated intracellular pathogens are notoriously difficult to identify through currently available testing methods, a consensus is needed to define a clinical endpoint that would be indicative of a cure. Dr. David Hahn has been pioneering the antimicrobial approach to treating asthma for decades, and authored a large research study (AMAZES). His trial confirmed the suspicion that patients with asthma could benefit from Azithromycin treatment.
Randomized, double-blind, placebo controlled parallel group trial, n = 420, Lancet, 2017
Methods- Azithromycin 500 mg or placebo three times per week for 48 weeks in adult patients (18 years or older) whose asthma remained poorly controlled in spite of inhaled corticosteroids with a LABA.
Results- Azithromycin reduced asthma exacerbations (1·07 per patient-year [95% CI 0·85-1·29]) compared with placebo (1·86 per patient-year [1·54-2·18]; incidence rate ratio [IRR] 0·59 [95% CI 0·47-0·74]; p<0·0001). The proportion of patients experiencing at least one asthma exacerbation was reduced by azithromycin treatment (127 [61%] patients in the placebo group vs 94 [44%] patients in the azithromycin group, p<0·0001). Azithromycin significantly improved asthma-related quality of life (adjusted mean difference, 0·36 [95% CI 0·21-0·52]; p=0·001). Diarrhoea was more common in azithromycin-treated patients (72 [34%] vs 39 [19%]; p=0·001).
Conclusions- Adults with persistent symptomatic asthma experience fewer asthma exacerbations and improved quality of life when treated with oral azithromycin for 48 weeks. Azithromycin might be a useful add-on therapy in persistent asthma.
Randomized, placebo-controlled, double-blinded trial, n = 97, JABFM, 2012
Methods- 12 weekly doses of adjunctive azithromycin, with follow-up to 1 year after randomization, in adults with persistent asthma.
Results- At 1 year, compared with the placebo arm, subjects randomized to azithromycin were more likely to have an AQL score ≥1 unit increase compared with baseline, but this difference was not statistically significant (36% vs 21% for placebo; P = .335). Compared with placebo, OL subjects had significant improvements in overall asthma symptoms from baseline (P = .0196), AQL (P = .0006), and asthma control (P = .0148).
Conclusions- Adults with asthma who were randomized to azithromycin did not show statistically significant improvement in asthma outcomes, although the study was underpowered to detect clinical improvement in 15% (number needed to treat = 7). Adults with severe persistent asthma who elected OL treatment documented clinical improvements in asthma symptoms, AQL, and asthma control that persisted after completion of OL azithromycin (number needed to treat = 2).
Two case-control studies, n= 66, PLoS One 2012.
Methods- (1) Prevalence of Cp IgE (measured by immunoblotting) and Cp DNA (by polymerase chain reaction) in peripheral blood, and biomarker associations with asthma severity. (2) Case-control studies of Cp IgE association with asthma using healthy blood donor (study 1) and non-asthmatic clinic patient (study 2) controls.
Results- Of 66 asthma subjects 33 (50%) were Cp IgE positive and 16 (24%) were Cp DNA positive (P = 0.001 for association of Cp IgE and DNA). Cp IgE was detected in 21% of mild intermittent asthma v 79% of severe persistent asthma (test for trend over severity categories, P = 0.002). Cp IgE detection was significantly (P = 0.001) associated with asthma when compared to healthy blood donor controls but not when compared to clinic controls.
Conclusions- Half of this sample of community asthma patients had detectable IgE against C. pneumoniae. Cp IgE was strongly and positively associated with asthma severity and with asthma when healthy blood donor controls were used. These results support the inclusion of Cp IgE as a biomarker in future studies of infectious contributions to asthma pathogenesis.
Randomized, placebo-controlled, blinded, allocation-concealed parallel group trial, PLoS Clinical Trials, 2006.
Methods- Adults with stable, persistent asthma given azithromycin (six weekly doses) or identical matching placebo, plus usual community care.
Results- Juniper AQLQ improved by 0.25 (95% confidence interval; -0.3, 0.8) units, overall asthma symptoms improved by 0.68 (0.1, 1.3) units, and rescue inhaler use decreased by 0.59 (-0.5, 1.6) daily administrations in azithromycin-treated compared to placebo-treated participants. Baseline IgA antibodies were positively associated with worsening overall asthma symptoms at follow-up (p = 0.04), but IgG was not (p = 0.63). Overall asthma symptom improvement attributable to azithromycin was 28% in high IgA participants versus 12% in low IgA participants (p for interaction = 0.27).
Conclusions- Azithromycin did not improve Juniper AQLQ but appeared to improve overall asthma symptoms. Larger community-based trials of antichlamydial antibiotics for asthma are warranted.
Case-control study, n = 138, Annals of Allergy Asthma and Immunology, 2008.
Methods- analyzed C pneumoniae– exposed primary care patients (86 adult asthmatic cases and 52 nonasthmatic controls) for seroreactivity against a C pneumoniae–specific hsp60 fragment and against the C trachomatis hsp60 molecule. Analyzed associations with asthma and irreversible lung remodeling as measured by means of postbronchodilator FEV-1.
Results- 27% of asthmatic patients were C pneumoniae hsp60 seropositive vs 8% of controls (P < .01). Controlling for age, sex, and smoking, C pneumoniae hsp60 seropositivity was associated with lower postbronchodilator FEV-1 in asthmatic patients (P < .05). No comparable associations were present for C trachomatis hsp60.
Conclusions- In individuals with evidence of previous exposure to C pneumoniae infection, a host antibody response against a C pneumoniae hsp60 fragment but not against C trachomatis hsp60 was associated with airflow limitation in adults with asthma.
Double-blind, randomized, placebo-controlled study, n = 278, New England Journal of Medicine, 2006.
Methods- Adults enrolled within 24 hours after an acute exacerbation of asthma requiring short-term medical care. Administered 10 days of oral treatment with telithromycin (at a dose of 800 mg daily) or placebo in addition to usual care.
Results- Of the two outcomes, only asthma symptoms showed a significantly greater reduction among patients receiving telithromycin than among those receiving placebo. Mean (±SD) scores on a test of asthma symptoms (on a 7-point scale, with 0 denoting no symptoms and 6 denoting severe symptoms) were 3.0±1.4 at baseline and 1.7±1.1 at the end of treatment for the telithromycin group and 2.8±1.3 at baseline and 2.0±1.0 at the end of treatment for the placebo group. The mean decrease in symptom scores during the treatment period was 1.3 for telithromycin and 1.0 for placebo (mean difference, −0.3; 95 percent confidence interval, −0.5 to −0.1; P=0.004). There was no significant treatment effect on the other primary outcome measure, a change in morning peak expiratory flow. Nausea was more common among patients in the telithromycin group than in the placebo group (P=0.01).
Conclusions- This study provides evidence of the benefit of telithromycin in patients with acute exacerbations of asthma; the mechanisms of benefit remain unclear.
Antibiotic activity assay of continuous C. pneumoniae infection in vitro, Antimicrobial Agents and Chemotherapy, 2002.
Methods- investigating the effect of higher concentrations and a longer duration of treatment with azithromycin, clarithromycin, or levofloxacin on the growth of C. pneumoniae ( 4 μg of azithromycin/ml, 16 μg of levofloxacin/ml, or 64 μg of clarithromycin/ml.
Results- The results of this study demonstrated that prolonged treatment with azithromycin, clarithromycin, and levofloxacin at concentrations achieved in the epithelial lining fluid reduced but did not eliminate C. pneumoniae from continuously infected host cells.
Conclusions- 1) The dosages of azithromycin being used in coronary artery disease secondary prevention are 500 or 600 mg/day for 3 and 6 days followed by weekly doses of 500 to 600 mg for periods of 3 months to 1 year. Based on the data presented here, it would appear unlikely that these dosage regimens would eliminate C. pneumoniae from an intravascular focus. 2) Existence of persistence also raises a separate important issue for the treatment of C. pneumoniae-associated diseases. Persistent forms generally do not replicate or have reduced activity and therefore may not be susceptible to antibiotics. It is quite possible that the 20 to 30% rate of microbiologic failures in reported C. pneumoniae treatment studies and the ability of C. pneumoniae to survive antibiotic treatment in our experiments may be directly related to the persistent state.
Prospective clinical, bacteriologic, and serologic study, also a matched comparison of patients with and without evidence of CpN infection. , n = 365, JAMA, 1991.
Methods- adult male patients (serologic titers greater than or equal to 1:64 and less than 1:16, respectively). Association of acute C pneumoniae infection with signs and symptoms of respiratory illness and the relationship of C pneumoniae antibody titer with wheezing at the time of enrollment in the study, and with the diagnosis of asthmatic bronchitis.
Results- Nine (47%) of 19 patients with acute C pneumoniae infection had bronchospasm during respiratory illness, and there was a strong quantitative association of C pneumoniae titer with wheezing at the time of enrollment in the study (P = .01).
In the matched study, C pneumoniae antibody was significantly associated with asthmatic bronchitis after, but not before, respiratory illness (odds ratio, 7.2; 95% confidence interval, 2.2 to 23.4). Four infected patients had newly diagnosed asthma after illness, and four others had exacerbation of previously diagnosed asthma.
Conclusions- Some C pneumoniae antibody titers, although not diagnostic of chlamydial infection by present criteria, probably represent acute reinfection or ongoing chronic infection. Repeated or prolonged exposure to C pneumoniae may have a causal association with wheezing, asthmatic bronchitis, and asthma.
For patients: www.asthmastory.com provides excellent context to the whole story, complete with patient accounts and a list of doctors across the US who treat asthma based on this body of research. It was created by Jim Quinlan, an asthma patient whose near-fatal asthma attack led to successful treatment with azithromycin.